Professor Ingunn Holen

School of Medicine and Population Health

Professor of Bone Oncology

Prof Ingunn Holen
Profile picture of Prof Ingunn Holen
i.holen@sheffield.ac.uk
+44 114 215 9011
Room GU24, The Medical School

Full contact details

Professor Ingunn Holen
School of Medicine and Population Health
Room GU24
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I studied Biology and Biochemistry at the University of Oslo, Norway, and was awarded my PhD for work on the role of autophagy in cancer in 1995. I then joined the University of Sheffield as a post-doctoral research associate working on the mechanism of action of bisphosphonates. Establishing a lab research program in breast cancer bone metastasis, I gained a lectureship in 2001 and was appointed as Professor of Bone Oncology in 2014.

Research interests

The research in my team is focussed on tumour cell dissemination in bone, and how this is influenced by the microenvironment in breast and prostate cancer. In particular we use cutting edge technology to study the early stages of bone metastasis and how single cancer cells may remain dormant or start to proliferate when encountering different environments.

We work to elucidate the molecular mechanisms involved in tumour cell-bone cell interactions, and how these can be targeted by anti-cancer therapies, including CDK4/6 inhibitors. We also investigate the role of the microenvironment in driving progression of bone metastases and collaborate with colleagues in the Dept of Physics and Astronomy to elucidate the biomechanical properties of the bone metastatic niche.

I have several collaborative projects both with other researchers in the medical school, nationally and internationally. I work closely with the clinical staff on translational research projects, transferring the results from our laboratory projects into clinical feasibility studies. Together with colleagues in Leeds, Glasgow and London I have established a national in vivo tissue bank for breast cancer research funded by an “Infrastructure for Impact” grant awarded by the . This initiative is entitled  and allows researchers to connect with partners who are wiling to share archived material on a collaborative basis thereby not having to carry out in vivo studies. Work in my team has been funded by local, regional and national charities, industry, the EU, MRC, CRUK, BCN, YCR and NC3Rs. In 2018, I and my colleague Dr Penelope Ottwell was awarded the “Julie Philipps PhD Studentship” from the charity  to support our work on the biology of secondary breast cancer. Our work on the mechanisms of tumour cell dormancy is supported by  and .

Ingunn Holden and Penelope Ottwell holding a cheque for £100,000 awarded from Second Hope
Publications

Journal articles

  • Theodoulou E, Martin C, Morgan J, Turner O, Hartup S, Achuthan R, Azmy I, Henderson J, Reed M, Holen I , Brown J et al (2025) . Journal of Geriatric Oncology, 16(7).
  • Holen I & Edwards C (2024) . Journal of Bone Oncology, 48, 100633-100633.
  • Llorente A, Blasco MT, Espuny I, Guiu M, Ballaré C, Blanco E, Caballé A, Bellmunt A, Salvador F, Morales A , Nuñez M et al (2023) . Nature Cell Biology, 25(12), 1833-1847.
  • Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I (2023) . Cancers, 15(8).
  • Thorne JL, Holen I & Corfe BM (2023) . Proceedings of the Nutrition Society, 82(1), 58-62.
  • Saleh L, Wilson C & Holen I (2021) . MedComm, 2(4), 514-530.
  • Porter I, Theodoulou E, Holen I, Harper-Wynne C, Baron-Hay S, Wilson C & Brown J (2021) . Journal of Bone Oncology, 31, 100402-100402.
  • Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK (2021) . Nanoscale, 13(43), 18237-18246.
  • Quayle LA, Spicer A, Ottewell PD & Holen I (2021) . Cancers, 13(16).
  • Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2021) . Physiological Reviews, 101(3), 797-855.
  • Hughes R, Chen X, Cowley N, Ottewell PD, Hawkins RJ, Hunter KD, Hobbs JK, Brown NJ & Holen I (2021) . Cancers, 13(6).
  • Chen X, Hughes R, Mullin N, Hawkins RJ, Holen I, Brown NJ & Hobbs JK (2020) . Biophysical Journal, 119(3), 502-513.
  • Ran R, Harrison H, Syamimi Ariffin N, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Mason SM, Blyth K , Holen I et al (2020) . Oncogene, 39(12), 2624-2637.
  • Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Abstracts: 2019 San Antonio Breast Cancer Symposium.
  • Saleh L, Wilson C & Holen I (2020) . Acta Oncologica, 59(2), 219-232.
  • Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alférez D, Wilkinson JM, Holen I , Clarke RB et al (2019) . Breast Cancer Research, 21(1).
  • Hughes R, Chen X, Hunter KD, Hobbs JK, Holen I & Brown NJ (2019) . The FASEB Journal, 33(11), 12768-12779.
  • Allocca G, Hughes R, Wang N, Brown HK, Ottewell PD, Brown NJ & Holen I (2019) . Journal of Bone Oncology, 17.
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) . Clinical Cancer Research, 25(9), 2769-2782.
  • Ran R, Harrison H, Ariffin NS, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Fowles AM, Blyth SMMK , Holen I et al (2019) .
  • Quayle LA, Ottewell PD & Holen I (2018) . Clinical & Experimental Metastasis, 35(8), 831-846.
  • Brown HK, Allocca G, Ottewell PD, Wang N, Brown NJ, Croucher PI, Eaton CL & Holen I (2018) . International Journal of Molecular Sciences, 19(10).
  • Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider M-T, Rhee CS, Qin Y, Gregory WM , Garrido-Castro AC et al (2018) . Cancer Research , 78(18).
  • Mittal S, Brown NJ & Holen I (2018) . Expert Review of Molecular Diagnostics, 18(3), 227-243.
  • Holen I, Speirs V, Morrissey B & Blyth K (2017) . Disease Models and Mechanisms, 10, 359-371.
  • Ubellacker JM, Haider MT, DeCristo MJ, Allocca G, Brown NJ, Silver DP, Holen I & McAllister SS (2017) . Breast Cancer Research, 19(1).
  • Morrissey B, Blyth K, Carter P, Chelala C, Jones L, Holen I & Speirs V (2017) . PLoS Biol, 15(1), e2000719-e2000719.
  • Morrissey B, Holen I, Chelala C, Carter P, Jones L, Blyth K & Speirs V (2016) . npj Breast Cancer, 2(1).
  • Wilson C, Brown H & Holen I (2016) . Endocrine-Related Cancer, 23, R567-R576.
  • Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE & Ottewell P (2016) . Oncotarget, 7, 75571-75584.
  • Holen I (2016) . Journal of Bone Oncology, 5(3), 87-89.
  • Carter P, Blyth K, Holen I, Jones L, Morrissey B, Speirs V & Chelala C (2016) . Open Journal of Bioresources, 3.
  • Speirs V, Morrisey B, Holen I, Blyth K, Carter P, Chelala C & Jones L (2016) . Breast Cancer Research and Treatment, 156(3), 447-452.
  • Morrissey B, Blyth K, Carter P, Chelala C, Jones L, Holen I & Speirs V (2016) . Breast Cancer Research, 18(1).
  • Holen I (2016) . Journal of Bone Oncology.
  • De Felice M, Lambert D, Holen I, Escott KJ & Andrew D (2016) . Molecular Pain, 12.
  • Blyth K, Carter P, Morrissey B, Chelala C, Jones L, Holen I & Speirs V (2016) . Breast Cancer Research and Treatment, 156(3), 447-452.
  • Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) . Journal of the National Cancer Institute, 108(4).
  • Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL & Ottewell PD (2016) . Clinical & Experimental Metastasis, 33(3), 211-224.
  • Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) . Annals of Oncology, 27(3), 379-390.
  • Morrissey B, Blyth K, Carter P, Chelala C, Holen I, Jones L & Speirs V (2015) . Alternatives to Laboratory Animals, 43(6), 367-375.
  • Wang N, Reeves KJ, Brown HK, Fowles ACM, Docherty FE, Ottewell PD, Croucher PI, Holen I & Eaton CL (2015) . JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 34.
  • Haider M-T, Hunter KD, Robinson SP, Graham TJ, Corey E, Dear TN, Hughes R, Brown NJ & Holen I (2015) . BONE, 81, 581-592.
  • Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL & Holen I (2015) . International Journal of Cancer, 137(4), 968-977.
  • Quayle L, Ottewell PD & Holen I (2015) . CURRENT CANCER DRUG TARGETS, 15(6), 469-480.
  • Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P & Ottewell PD (2015) . Clinical & Experimental Metastasis, 32(7), 689-702.
  • Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI & Eaton CL (2015) . FASEB Journal, 29(8), 3141-3150.
  • Talari ACS, Evans CA, Holen I, Coleman RE & Rehman IU (2015) . Journal of Raman Spectroscopy, 46(5), 421-427.
  • Ottewell PD, O'Donnell L & Holen I (2015) . Bonekey Reports, 4, 643.
  • Wilson C, Ottewell P, Coleman RE & Holen I (2015) . BMC Cancer, 15.
  • Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles ACM, Ottewell PD, Dear TN, Holen I, Croucher PI & Eaton CL (2014) . J Bone Miner Res, 29(12), 2688-2696.
  • Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) . Endocrine Related Cancer, 21(5), 769-781.
  • Haider M-T, Holen I, Dear TN, Hunter K & Brown HK (2014) . Bone, 66(100), 240-250.
  • Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) . Clinical Cancer Research, 20(11), 2922-2932.
  • Dougall WC, Holen I & González Suárez E (2014) . Bonekey Rep, 3, 519.
  • Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) . Endocr Relat Cancer, 21(2), 327-341.
  • David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RL , Jurdic P et al (2014) . Journal of Biological Chemistry, 289(10), 6551-6564.
  • Mashima I & Nakazawa F (2013) . Journal of Oral Biosciences, 55(4), 184-190.
  • Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD & Holen I (2013) . Cell Oncol (Dordr), 36(6), 505-514.
  • Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE , Bundred NJ et al (2013) . Breast Cancer Research(5), R92.
  • Coleman RE, Gregory W, Marshall H, Wilson C & Holen I (2013) . The Breast, 22(Sup 2), S50-S56.
  • Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S , Holen I et al (2013) . Clin Cancer Res, 19(10), 2755-2765.
  • Vasiliadou I & Holen I (2013) . Journal of Bone Oncology, 2(4), 158-166.
  • Wilson C, Winter MC, Holen I, Freeman JV, Evans AC & Coleman RE (2012) . Cancer Research, 72(24_Supplement).
  • Holen I, Wang N, Reeves KJ, Fowles AM, Croucher PI, Eaton CL & Ottewell PD (2012) . Cancer Research, 72(24_Supplement).
  • Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2012) A single administration of combination therapy inhibits breast tumour progress bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology, 1(2), 47-56.
  • Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2012) . Breast Cancer Res, 14(3), R86.
  • Brown HK, Ottewell PD, Evans CA & Holen I (2012) . Clin Exp Metastasis, 29(8), 927-938.
  • Wilson C, Holen I & Coleman RE (2012) . Cancer Treat Rev, 38(7), 877-889.
  • Michailidou M & Holen I (2012) . Recent Results Cancer Res, 192, 145-169.
  • Ottewell PD, Whitworth J, Cross SS, Nutter FH & Holen I (2011) . Cancer Research, 71(24_Supplement).
  • Rogers TL & Holen I (2011) . Journal of Translational Medicine, 9(1).
  • Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE & Holen I (2011) Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Research and Treatment, 1-14.
  • Wind NS & Holen I (2011) . Int J Breast Cancer, 2011, 967419.
  • Brown HK, Ottewell PD, Coleman RE & Holen I (2011) . J Cell Mol Med, 15(3), 501-513.
  • Holen I & Coleman RE (2010) . Breast Cancer Res, 12(6), 214.
  • Syddall SP, Ottewell PD & Holen I (2010) . Curr Pharm Des, 16(27), 2988-2997.
  • Kobayashi-Sakamoto M, Isogai E & Holen I (2010) . EUR J HAEMATOL, 85(1), 26-35.
  • Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P , Holen I et al (2010) . Cancer Treat Rev, 36(8), 615-620.
  • Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, Brown NJ & Holen I (2010) . J Vasc Res, 47(6), 481-493.
  • Holen I & Coleman RE (2010) . Curr Pharm Des, 16(11), 1262-1271.
  • Neville-Webbe HL, Coleman RE & Holen I (2010) . Br J Cancer, 102(6), 1010-1017.
  • Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE & Holen I (2010) . Int J Cancer, 126(2), 522-532.
  • Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G , Musiani P et al (2010) . J Cell Mol Med, 14(12), 2803-2815.
  • Clyburn RD, Reid P, Evans CA, Lefley DV & Holen I (2010) . Cancer Chemother Pharmacol, 65(5), 969-978.
  • Brown HK & Holen I (2009) . Curr Cancer Drug Targets, 9(7), 807-823.
  • Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE & Holen I (2009) . Mol Cancer Ther, 8(10), 2821-2832.
  • Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang D, Holen I, Done SJ & Clemons M (2009) . CLIN EXP METASTAS, 26(8), 935-943.
  • Reid PE, Brown NJ & Holen I (2009) . Mol Cancer, 8, 49.
  • Xue X, Teare MD, Holen I, Zhu YM & Woll PJ (2009) . Clin Chim Acta, 404(2), 100-104.
  • Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) . Journal of Clinical Oncology, 27(15_suppl), e11625-e11625.
  • Ottewell PD, Lefley DV, Coleman RE & Holen I (2009) . Cancer Research, 69(2_Supplement), 2151-2151.
  • Reid P & Holen I (2009) . Eur J Cell Biol, 88(1), 1-17.
  • Cross NA, Fowles A, Reeves K, Jokonya N, Linton K, Holen I, Hamdy FC & Eaton CL (2008) . Prostate, 68(15), 1707-1714.
  • Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE & Holen I (2008) . J Natl Cancer Inst, 100(16), 1167-1178.
  • Winter MC, Holen I & Coleman RE (2008) . Cancer Treat Rev, 34(5), 453-475.
  • Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) . Clin Cancer Res, 14(14), 4658-4666.
  • Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, Auriola S & Mönkkönen J (2008) . Anti-Cancer Drugs, 19(4), 391-399.
  • Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R , Steel M et al (2008) . BREAST CANCER RES, 10(2).
  • Cross NA, Waterman EA, Jokonya N, Fowles A, Buckle CH, Phillips J, Holen I, Hamdy FC & Eaton CL (2008) . J Cell Biochem, 104(4), 1452-1464.
  • Holen I (2008) . Cancer Treatment Reviews, 34, 49-49.
  • Woodward JKL, Holen I, Coleman RE & Buttle DJ (2007) . Bone, 41(6), 912-927.
  • Mönkkönen H, Ottewell PD, Kuokkanen J, Mönkkönen J, Auriola S & Holen I (2007) . Life Sci, 81(13), 1066-1070.
  • Xue X, Teare MD, Holen I, Zhu YM & Woll PJ (2007) . Journal of Thoracic Oncology, 2(8), S514-S515.
  • Waterman EA, Cross NA, Lippitt JM, Cross SS, Rehman I, Holen I, Hamdy FC & Eaton CL (2007) . Int J Cancer, 121(9), 1958-1966.
  • Vincenzi B, Santini D, Holen I & Tonini G (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Haematologica Reports, 2(3), 50-51.
  • Michailidou M, Neville-Webbe HL, Woodward JK, Lefley DV, Brown NJ, Coleman RE & Holen I (2006) The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro. Haematologica Reports, 2(3), 48-49.
  • Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A & Tonini G (2006) . NAT CLIN PRACT ONCOL, 3(6), 325-338.
  • Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A , Caraglia M et al (2006) Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. ONCOL REP, 15(5), 1351-1357.
  • Cross N, Waterman E, Jokonya N, Holen I, Hamdy F & Eaton C (2006) . European Urology Supplements, 5(2), 124-124.
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2006) . Tumour Biol, 27(2), 92-103.
  • Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2006) . J Clin Pathol, 59(7), 716-720.
  • Holen I & Shipman CM (2006) . Clin Sci (Lond), 110(3), 279-291.
  • Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE & Holen I (2006) . J Clin Pathol, 59(1), 56-63.
  • Ottewell PD, Coleman RE & Holen I (2006) . Breast Cancer Res Treat, 96(2), 101-113.
  • Cross SS, Yang Z, Brown NJ, Balasubramanian SP, Evans CA, Woodward JK, Neville-Webbe HL, Lippitt JM, Reed MWR, Coleman RE & Holen I (2006) . Int J Cancer, 118(8), 1901-1908.
  • Santini D, Vincenzi B, Hannon RA, Brown J, La Cesa A, Holen I & Tonini G (2005) Correlations of vessel endothelial growth factor (VEGF) and B crosslinked type I collagen C-telopeptide (bCTX) after a single zoledronic acid infusion in patients with tumour-induced bone disease. ANN ONCOL, 16, 32-32.
  • Woodward JKL, Neville-Webbe HL, Coleman RE & Holen I (2005) . Anticancer Drugs, 16(8), 845-854.
  • Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE & Eaton CL (2005) . Breast Cancer Res Treat, 92(3), 207-215.
  • Woodward JKL, Coleman RE & Holen I (2005) . Anticancer Drugs, 16(1), 11-19.
  • Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE & Holen I (2005) . Int J Cancer, 113(3), 364-371.
  • Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC & Eaton CL (2004) . J Bone Miner Res, 19(10), 1712-1721.
  • Gilbey AM, Burnett D, Coleman RE & Holen I (2004) . J CLIN PATHOL, 57(9), 903-911.
  • Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE & Holen I (2004) . Breast Cancer Res Treat, 86(3), 269-279.
  • Eaton CL, Wells JM, Holen I, Croucher PI & Hamdy FC (2004) . Prostate, 59(3), 304-310.
  • Chandrasekharan S, Hamdy FC, Holen I, Cross N & Buttle DJ (2003) . European Urology Supplements, 2(1), 60-60.
  • Holen I, Croucher PI, Hamdy FC & Eaton CL (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.. Cancer Res, 62(6), 1619-1623.
  • Holen I, Eaton C, Hamdy F & Croucher P (2002) . European Urology Supplements, 1(1), 54-54.
  • Wells J, Holen I, Croucher P, Hamdy F & Eaton C (2002) . European Urology Supplements, 1(1), 159-159.
  • Neville-Webbe HL, Holen I & Coleman RE (2002) . Cancer Treat Rev, 28(6), 305-319.
  • Vankemmelbeke MN, Holen I, Wilson AG, Ilic MZ, Handley CJ, Kelner GS, Clark M, Liu C, Maki RA, Burnett D & Buttle DJ (2001) . Eur J Biochem, 268(5), 1259-1268.
  • Holen I, Drury NL, Hargreaves PG & Croucher PI (2001) . Br J Haematol, 114(2), 414-421.
  • Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM , Dunstan CR et al (2001) . Blood, 98(13), 3534-3540.
  • Shipman CM, Holen I, Lippitt JM, Vandenberghe E & Croucher PI (2000) Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.. BLOOD, 96(11), 360A-360A.
  • Ilic MZ, Vankemmelbeke MN, Holen I, Buttle DJ, Clem Robinson H & Handley CJ (2000) . Matrix Biol, 19(3), 257-265.
  • Holen I, Dury NL, Hargreaves PG & Croucher PI (2000) Human myeloma cells shed syndecan-1 in vitro: Evidence for mediation by a non-matrix metallproteinase.. J BONE MINER RES, 15(6), 1222-1222.
  • Shipman CM, Holen I, Lippitt JM, Edwards T & Croucher PI (2000) Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.. J BONE MINER RES, 15(6), 1217-1217.
  • Luckman SP, Hughes DE, Chilton KM, Coxon FP, Holen I, Russell RGG, Ebetino FH & Rogers MJ (1997) Bisphosphonates act by inhibiting protein prenylation.. J BONE MINER RES, 12, T372-T372.
  • Holen I, Gordon PB, Strømhaug PE & Seglen PO (1996) . European Journal of Biochemistry, 236(1), 163-170.
  • Seglen PO, Berg TO, Blankson H, Fengsrud M, Holen I & Strømhaug PE (1996) , 103-111.
  • Holen I, Gordon PB, Strømhaug PE, Berg TO, Fengsrud M, Brech A, Roos N, Berg T & Seglen PO (1995) . Biochemical Journal, 311(1), 317-326.
  • Holen I, Str PE, Gordon PB, Fengsrud M, Berg TO & Seglen PO (1995) . Journal of Biological Chemistry, 270(21), 12823-12831.
  • Gordon PB, Holen I & Seglen PO (1995) . Journal of Biological Chemistry, 270(11), 5830-5838.
  • Blankson H, Holen I & Seglen PO (1995) . Experimental Cell Research, 218(2), 522-530.
  • HOLEN I, GORDON PB & SEGLEN PO (1993) . European Journal of Biochemistry, 215(1), 113-122.
  • Gordon PB, Holen I, Fosse M, Røtnes JS & Seglen PO (1993) . Journal of Biological Chemistry, 268(35), 26107-26112.
  • Holen I, Gordon PB & Seglen PO (1992) . Biochemical Journal, 284(3), 633-636.
  • Seglen PO, Gordon PB, Holen I & Hoyvik H (1991) Hepatocytic autophagy. Biomedica Biochimica Acta, 50(4-6), 373-381.
  • Seglen PO, Gordon PB & Holen I (1990) Non-selective autophagy.. Seminars in Cell Biology, 1(6), 441-448.
  • Holen I, Mikalsen S & Sanner T (1990) . Journal of Toxicology and Environmental Health, 29(1), 89-98.
  • Mikalsen S-O, Holen I & Sanner T (1990) . Cell Biology and Toxicology, 6(1), 1-13.
  • Bradbury S, Rennicks S, Evans A, del CBM, Holen I & Ottewell P () . Bone Abstracts.
  • Haider M-T, Ottewell PD, Brown NJ, Lefley DV & Holen I () . Bone Abstracts.
  • Wilson C, Nutter F, Brown H, Coleman R & Holen I () . Bone Abstracts.

Book chapters

  • Holen I, Saleh L, Ottewell PD & Lawson MA (2022) , Bone Cancer (pp. 35-53). Elsevier
  • Holen I & Quayle L (2021) , Advances in Stem Cells and their Niches (pp. 35-62). Elsevier
  • Coleman RE, Brown J & Holen I (2020) , Abeloff's Clinical Oncology (pp. 809-830.e3). Elsevier
  • Alix-Panabieres C, Arlt MJE, Bataille R, Bedard G, Berthold DR, Bianco P, Blanchard F, Blay J-Y, Bolton D, Bolzoni M , Born W et al (2015) , Bone Cancer (pp. xi-xv). Elsevier
  • Holen I & Lawson MA (2015) , Bone Cancer (pp. 503-518). Elsevier
  • Holen I & Lawson MA (2015) , Bone Cancer Primary Bone Cancers and Bone Metastases Second Edition (pp. 503-518).
  • Coleman RE & Holen I (2014) , Abeloff's Clinical Oncology (pp. 739-763.e3). Elsevier
  • Coleman RE & Holen I (2013) , Abeloff S Clinical Oncology Fifth Edition (pp. 739-763).
  • Holen I & Lawson MA (2010) , Bone Cancer (pp. 347-363).
  • Ando K, Arslandemir C, Bell WC, Berdal A, Berthold D, Bhat BM, Bhat RA, Bhattacharyya S, Billiard J, Blanchard F , Bodine PVN et al (2010) , Bone Cancer (pp. xi-xv). Elsevier
  • Holen I & Lawson MA (2010) , Bone Cancer (pp. 347-363). Elsevier
  • Abbruzzese JL, Abeloff MD, Abou-Alfa GK, Abrahm JL, Abrams JS, Acs G, Aisner J, Aisner SC, Alani RM, Alberts SR , Ambinder RF et al (2008) , Abeloff's Clinical Oncology (pp. xi-xxvi). Elsevier
  • Coleman RE & Holen I (2008) , Abeloff's Clinical Oncology (pp. 845-871). Elsevier
  • Croucher PI, Holen I & Hargreaves PG (2000) , Novel Cytokine Inhibitors (pp. 103-122). Birkhäuser Basel
  • Seglen PO, Holen I & Gordon PB (1993) , Molecular Mechanisms of Membrane Traffic (pp. 339-349). Springer Berlin Heidelberg
  • Seglen PO, Gordon PB, Holen I, Høyvik H, Kovács AL, Strømhaug PE & Berg TO (1992) , Endocytosis (pp. 247-254). Springer Berlin Heidelberg
  • Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R & Costa L () Springer Science and Business Media LLC

Conference proceedings

  • Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) . Cancer Research, Vol. 80(4_Supplement)
  • Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
  • Holen I (2020) Highlights of the last year: basic research. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 587-587)
  • Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) . Cancer Research, Vol. 79(4_Supplement)
  • Hughes R, Ottewell P, Hobbs J, Holen I & Brown NJ (2019) Breast Cancer Metastasis to Bone: The Role of the Perivascular Niche in Regulating Tumour Cell Dormancy. JOURNAL OF VASCULAR RESEARCH, Vol. 56 (pp 17-18)
  • Chen X, Hughes R, Mullin N, Hawkins R, Holen I, Brown N & Hobbs J (2019) Supracellular Mechanical Architecture of the Intact Bone Microenvironment. EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, Vol. 48 (pp S100-S100)
  • Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Haider M-T, Rhee CS, Qin Y, Holen I, Gregory WM , Brown JE et al (2018) . Molecular Cancer Research, Vol. 16(8_Supplement) (pp B13-B13)
  • (2018) . Breast Cancer Research and Treatment, Vol. 167(1) (pp 309-405)
  • Lefley D, Nutter F, Brown H, Tulotta C, Eyre R, Clarke R, Alferez D, Wilkinson M, Holen I & Ottewell P (2017) . Clinical and Experimental Metastasis , Vol. 34(8) (pp 516-516). Berlin, Germany , 27 November 2017 - 27 November 2017.
  • Haider MT, Holen I, Brown NJ & Hunter K (2015) SHORT-TERM IN VIVO ADMINISTRATION OF CABOZANTINIB INDUCES RAPID MODIFICATION OF THE BONE MARROW VASCULARITY. JOURNAL OF VASCULAR RESEARCH, Vol. 52 (pp 28-28)
  • Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Marshall H, Banks RE, Selby PJ, Coleman RE & Brown JE (2013) . Cancer Research, Vol. 73(24_Supplement)
  • Byrne M, Ottewell PD, Holen I, Sanderson T & Cross SS (2012) The Use of p63 in Distinguishing In Situ and Invasive Tumour in the PyMT Mouse Model of Breast Cancer. JOURNAL OF PATHOLOGY, Vol. 228 (pp S38-S38)
  • Kobayashi-Sakamoto M, Isogai E, Hirose K, Okumura K, Holen I & Chiba I (2011) THROMBIN INDUCES OSTEOPROTEGERIN PRODUCTION VIA PHOSPHATIDYLINOSITOL 3-KINASE PATHWAY IN HUMAN MICROVASCULAR ENDOTHELIAL CELLS. INFLAMMATION RESEARCH, Vol. 60 (pp 216-217)
  • Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) . BONE, Vol. 48 (pp S255-S255)
  • Ottewell PD, Whitworth J & Holen I (2011) THE ROLE OF PLAKOGLOBIN IN THE INITIATION OF BREAST CANCER METASTASES. ANNALS OF ONCOLOGY, Vol. 22 (pp 32-32)
  • Brown JE, Cameron D, Coleman R, Fallowfield L, Holen I, Jones AL & Thompson A (2011) UK INNOVATORS IN BREAST CANCER: AN INITIATIVE TO SUPPORT THE NEXT GENERATION OF BREAST CANCER RESEARCHERS (ON BEHALF OF PAST AND PRESENT 'UK INNOVATORS'). ANNALS OF ONCOLOGY, Vol. 22 (pp 58-58)
  • Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
  • Lunj S, Staton CA, Holen I, Ballmer-Hofer K, Reed MW & Brown NJ (2011) . Cancer Research, Vol. 71(8_Supplement) (pp 5131-5131)
  • Ottewell PD, Brown H, Evans CA, Wind NS, Brown NJ, Coleman RE & Holen I (2011) . BONE, Vol. 48(1) (pp S42-S42)
  • Wind NS, Brown H, Ottewell PD, Sadej R, Romanska H, Berditchevski F & Holen I (2011) . BONE, Vol. 48(1) (pp S45-S45)
  • Brown* HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) . Bone, Vol. 48(1) (pp S41-S41)
  • Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) . BONE, Vol. 48(1) (pp S33-S33)
  • Brown HK, Ottewell PD, Evans CA & Holen I (2011) . BONE, Vol. 48(1) (pp S40-S41)
  • Winter MC, Evans A, Holen I & Coleman RE (2011) . BONE, Vol. 48(1) (pp S30-S31)
  • Winter MC, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Mori S, Holen I & Coleman RE (2010) . Cancer Research, Vol. 70(24_Supplement)
  • Holen I, Ottewell PD & Coleman RE (2010) . Cancer Research, Vol. 70(24_Supplement)
  • Ottewell PD, Lefely DV, Cross SS, Coleman RE & Holen I (2010) . BONE, Vol. 47 (pp S317-S317)
  • Brown HK, Ottewell PD, Lefely DV, Coleman RE & Holen I (2010) . BONE, Vol. 47 (pp S318-S319)
  • Winter MC, Evans A, Holen I & Coleman RE (2010) . BONE, Vol. 47 (pp S310-S310)
  • Woodward J, Holen I, Lefley D, Ottewell P & Buttle D (2010) Breast cancer-bone marrow stromal cell interactions modify expression of proteolytic enzymes and regulators of bone turnover. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 91(2) (pp A45-A46)
  • Bundred NJ, Landberg G, Coleman RE, Morris J, Winter MC, Holen I, Cramer A, Renshaw L, Grassby S & Dixon JM (2009) Short-term biological effects of zoledronic acid combined with letrozole in postmenopausal women with estrogen receptor-positive invasive breast cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 27(15)
  • Winter MC, Cross SS, Ingram CE, Jolley IJ, Holen I, Hatton MQ, Horsman JM & Coleman R (2009) ANZAC: A NEOADJUVANT BIOMARKER STUDY EXPLORING THE ANTI-TUMOUR ACTIVITY OF THE ADDITION OF ZOLEDRONIC ACID TO CHEMOTHERAPY IN BREAST CANCER. ANNALS OF ONCOLOGY, Vol. 20 (pp 55-55)
  • Ottewell PD, Leftey DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 200S-201S)
  • Offewell P, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. EJC SUPPLEMENTS, Vol. 6(9) (pp 18-18)
  • Lefley DV, Holen I, Coleman RE & Ottewell PD (2008) . BREAST CANCER RESEARCH, Vol. 10 (pp S40-S40)
  • Ottewell PD, Lefley DV, Coleman RE & Holen I (2008) . BREAST CANCER RESEARCH, Vol. 10 (pp S40-S41)
  • Ottewett P, Coleman R & Holen I (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S62-S62)
  • Ottewett P, Croucher P & Holen I (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S56-S56)
  • Brown HK & Holen I (2008) . CANCER TREATMENT REVIEWS, Vol. 34 (pp S60-S61)
  • Woodward J, Lefley D, Cross N, Ottewell PD, Buttle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A97-A97)
  • Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
  • Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
  • Woodward JKL, Lefley DV, Cross NA, Ottewell PD, Battle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1142-1143)
  • Van Pozanki C, Otterwell P, Cross S, Hudis C, Coleman RE & Holen I (2007) Osteoprotegerin (OPG) expression in breast tumors and bone metastases. INT J BIOL MARKER, Vol. 22(1) (pp 83-84)
  • Holen I, Neville-Webbe H & Coleman RE (2006) . BREAST CANCER RESEARCH, Vol. 8 (pp S4-S4)
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) . BREAST CANCER RESEARCH, Vol. 8 (pp S17-S17)
  • Michailidou M, Brown N, Coleman RE & Holen I (2006) . BREAST CANCER RESEARCH, Vol. 8 (pp S18-S18)
  • Kuokkanen J, Monkkonen H, Evans A, Holen I, Jauhiainen M, Auriola S & Monkkonen J (2006) The bisphosphonate treatment related ATP analog formation in different cancer cell lines. BONE, Vol. 39(5) (pp S32-S32)
  • Holen I, Santini D, Vincenzi B, Tonini G & Hannon RA (2006) . BONE, Vol. 38(3) (pp S75-S75)
  • Michailidou M, Neville-Webbe HL, Evans CA, Brown NJ, Coleman RE & Holen I (2006) . BONE, Vol. 38(3) (pp S57-S58)
  • Monkkonen H, Holen I, Evans A, Jauhiainen M, Auriola S & Monkkonen J (2006) . BONE, Vol. 38(3) (pp S58-S58)
  • Neville-Webbe HL, Lefley D, Coleman RE & Holen I (2006) . BONE, Vol. 38(3) (pp S58-S59)
  • Van Poznak C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2006) . BONE, Vol. 38(3) (pp S31-S32)
  • Holen I, Patel R, Lefley DV, Webbe HLN, Coleman RE & Woodward JKL (2006) . BONE, Vol. 38(3) (pp S51-S52)
  • Kuokkanen J, Monkkonen H, Holen I, Evans CA, Kotilainen HK, Auriola S & Monkkonen J (2006) . BONE, Vol. 38(3) (pp S54-S54)
  • Cross SS, Ottewell P, Swinscoe M, Majeed AW & Holen I (2006) Osteoprotegerin is strongly expressed in the intratumoural endothelial cells of gastrointestinal carcinomas. JOURNAL OF PATHOLOGY, Vol. 208 (pp 9A-9A)
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
  • Holen I, Hannon RA, Ellis SP, Coleman RE & Brown JE (2006) Effects of clodronate on serum osteoprotogerin (OPG) in patients with metastatic bone disease. CANCER TREATMENT REVIEWS, Vol. 32 (pp S40-S40)
  • Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S290-S290)
  • Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) is expressed in human breast cancers and has a significant negative association with tumours with poor prognosis.. JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
  • Cross SS, Balasubramanian SP, Lippitt JM, Evans CA, Reed MWR & Holen I (2005) There is a general loss of expression of receptor activator of nFkB ligand (RANKL) in human breast cancers but retention of expression has a significant negative association with expression of oestrogen receptor (ER). JOURNAL OF PATHOLOGY, Vol. 207 (pp 27-27)
  • Woodward JKL, Neville-Webbe H, Coleman RE & Holen I (2005) The effects of zoledronic acid and doxorubicin in combination on breast cancer cell invasion in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(7) (pp 1299-1299)
  • Cross SS, Yang Z, Woodward JKL, Balasubramanian SP, Reed MWR, Coleman RE, Brown NJ & Holen I (2005) Tumour endothelial cells express osteoprotegerin (OPG) - A potential role in tumour angiogenesis?. CANCER TREATMENT REVIEWS, Vol. 31 (pp S37-S38)
  • Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S41-S41)
  • Woodward J, Coleman R, Neville-Webbe H & Holen I (2005) The combined effects of zoledronic acid (ZOL) and doxorubicin (DOX) on breast cancer cell invasion in vitro. CANCER TREATMENT REVIEWS, Vol. 31 (pp S43-S43)
  • Neville-Webbe HL, Coleman RE & Holen I (2005) Understanding drug-sequence-dependent synergistic induction of apoptosis by zoledronic acid (ZOL) and doxorubicin (DOX) in breast cancer. CANCER TREATMENT REVIEWS, Vol. 31 (pp S28-S28)
  • Evans CA, Neville-Webbe HL, Coleman RE & Holen I (2005) Differential induction of apoptosis following sequential treatments using cytotoxic drugs and zoledronic acid. CANCER TREATMENT REVIEWS, Vol. 31 (pp S36-S36)
  • Croucher P, Holen I & Eaton C (2005) Nonosseous effects of osteoprotegerin. CANCER TREATMENT REVIEWS, Vol. 31 (pp S14-S15)
  • Spencer A, Cross SS, Holen I, Ackroyd R, Stoddard CJ & Bury JP (2004) Expression of osteoprotegerin (OPG) and TRAIL in oesophageal carcinoma and non-neoplastic gastric and oesophageal mucosa. JOURNAL OF PATHOLOGY, Vol. 204 (pp 50A-50A)
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Zoledronic acid (ZOL) in combination with doxorubicin (DOX) has synergistic effects on apoptosis of breast cancer cells (BCCs) in vitro. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1598-1598)
  • Cross SS, Balasubramanian SP, Evans CA, Reed MWR & Holen I (2004) Osteoprotegerin is overexpressed in breast cancers and intratumoural endothelial cells and is significantly associated with tumour grade but not with axillary lymph node metastasis. JOURNAL OF PATHOLOGY, Vol. 204 (pp 14A-14A)
  • Nyambo R, Neville-Webbe H, Holen I, Cross NA, Hamdy FC & Eaton CL (2004) Human bone marrow stromal cells protect prostate and breast cancer cells from TRAIL-induced apoptosis. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1572-1572)
  • Eaton CL, Wells JM, Holen I, Croucher PI & Hamdy FC (2004) Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(9) (pp 1585-1585)
  • Neville-Webbe HL, Evans CA, Coleman RE & Holen I (2004) Combined treatments of breast cancer cells using bisphosphonates and doxorubicin. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 19(6) (pp 1035-1035)
  • Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and paclitaxel have synergistic antitumor activity and induce apoptotic tumor cell death at clinically relevant concentrations. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S132-S132)
  • Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Sequential exposure of breast cancer cells to cytotoxic agents and zoledronic acid induces synergistic increase in apoptotic cell death.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S72-S72)
  • Neville-Webbe HL, Evans A, Coleman RE & Holen I (2004) Presence of BRCA1 gene enhances levels of apoptosis induced by combination treatment with doxorubicin (DOX) and zoledronic acid (ZOL).. BREAST CANCER RESEARCH AND TREATMENT, Vol. 88 (pp S73-S73)
  • Van Poznac C, Cross SS, Saggese M, Lippitt JM, Hudis C, Coleman RE & Holen I (2004) Human breast cancers express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis inducing ligand (TRAIL) and receptor activator of nFkB ligand (RANKL). BONE, Vol. 34 (pp S29-S29)
  • Evans A, Neville-Webbe H, Coleman RE & Holen I (2004) Zoledronic acid and TRAIL induce synergistic increase in apoptotic tumor cell death. BONE, Vol. 34 (pp S56-S56)
  • Neville-Webbe H, Coleman RE & Holen I (2004) Paclitaxel and zoledronic acid induce synergistic increase in apoptotic tumour cell death at clinically relevant concentrations. BONE, Vol. 34 (pp S67-S68)
  • Cross SS, Van Poznak C, Hudis C & Holen I (2003) The expression of osteoprotegerin co-localises with columnar cell change in human breast tissue. JOURNAL OF PATHOLOGY, Vol. 201 (pp 32A-32A)
  • Van Poznak CH, Cross SS, Hudis C, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin expression correlates with ER/PR status in human breast tumors.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18 (pp S310-S310)
  • Naylor KE, Rogers A, Smith C, Hall V, Fraser RB, Holen I, Lippitt J, Eastell R & Blumsohn A (2003) Source of maternal serum osteoprotegerin during human pregnancy. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 18(7) (pp 1376-1376)
  • Neville-Webbe HL, Evans A, Eaton C, Coleman R & Holen I (2003) Bone marrow stromal cell-derived osteoproteger in (OPG) protects breast cancer cells from trail-induced apoptosis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S25-S25)
  • Nyambo R, Cross NA, Lippit J, Holen I, Bryden AAG & Eaton CL (2003) Human bone marrow stromal cells (hBMSC) protect prostate cancer cells from trail induced apoptosis. BRITISH JOURNAL OF CANCER, Vol. 88 (pp S26-S26)
  • Chandrasekharan S, Buttle DJ, Holen I, Cross NA & Hamdy FC (2003) Expression pattern of the ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) proteinases in human prostate cancer celllines. JOURNAL OF UROLOGY, Vol. 169(4) (pp 58-58)
  • Van Poznak CH, Cross SS, Hudis C, Norton L, Panageas KS, Coleman RE & Holen I (2003) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) are expressed in human breast tumors.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 82 (pp S162-S162)
  • Holen I, Wells JM, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Jagdev SP, Hamdy FC & Eaton CL (2002) The role of osteoprotegerin in breast and prostate cancer. J BONE MINER RES, Vol. 17(7) (pp 1339-1339)
  • Holen I, Croucher PI, Evans AC, Lippitt JM, Hamdy FC, Coleman RE & Eaton CL (2002) OPG is a survival factor for breast- and prostate cancer cells in vitro. BONE, Vol. 30(3) (pp 28S-28S)
  • Gordon PB, Holen I & Seglen PO (1991) Effects of adrenergic agonists and antagonists on autophagic activity in isolated rat liver cells. Biomedica Biochimica Acta, Vol. 50(4-6) (pp 383-387)
  • Holen I, Gordon PB & Seglen PO (1991) Role of cyclic nucleotides in the control of hepatic autophagy. Biomedica Biochimica Acta, Vol. 50(4-6) (pp 389-392)

Digital content

  • Holen I (2015) . Retrieved from

Other

  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
  • Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury SMJ et al (2023) .
Research group

PhD students

  • Elisavet Theodoulou
  • Jacky Wong
Professional activities and memberships

I am a Trustee of Breast Cancer Now and a member of the executive committee that organises the biannual UK Interdisciplinary Breast Cancer Symposium.

I have served as the Chair of the British Association for Cancer Research and am a current member of  national and international expert review panels, grant committees and journal editorial boards.